PE/Cyanine7 anti-human CD4 Antibody
- 产品名称：
- PE/Cyanine7 anti-human CD4 Antibody
- 产品类别：
- 抗体
- 产品编号：
- 357409
- 产品应用：
- 357409
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Human CD4 T cells
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography and conjugated with PE/Cyanine7 under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Additional Product Notes
- BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
- Product Citations
-
- Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
- Minns D, et al. 2021. Front Immunol. 12:633486. PubMed
- Hearnden R, et al. 2021. STAR Protocols. 2(2):100422. PubMed
- Wang K, et al. 2020. Signal Transduct Target Ther. 0.404861111. PubMed
- Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
- Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
- Park JA, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(5):. PubMed
- Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
- Mu Z, et al. 2021. Genome Biol. 122:22. PubMed
- Luo Y, et al. 2021. Nat Commun. 12:3913. PubMed
- Su X, et al. 2022. J Transl Med. 20:378. PubMed
- Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
- Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
- Le J, et al. 2020. Immunity. 52(6):1105-1118.e9. PubMed
- Park JA, et al. 2020. J Hematol Oncol. 0.661111111. PubMed
- Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
- ?yszkiewicz M, et al. 2020. Nat Commun. 11:1031. PubMed
- Pekayvaz K, et al. 2022. Nat Commun. 13:1018. PubMed
- Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
- RRID
- AB_2565661 (BioLegend Cat. No. 357409) AB_2565662 (BioLegend Cat. No. 357410)
- Structure
- 55 kD, type I transmembrane glycoprotein, member of the Ig superfamily
- Distribution
-
Helper T cells, subset of thymocytes, monocytes/macrophages, type II NKT cells
- Interaction
- Part of the TCR/CD3 complex
- Ligand/Receptor
- β2 domain from the MHC class II
- Cell Type
- T cells, Monocytes, Macrophages, NKT cells
- Biology Area
- Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
1. Zhu J, et al. 2010. Annu Rev. Immunol. 28:445.
2. Vignali DA. 2010. J. Immunol. 184:5933.
3. Zhou L, et al. 2009. Immunity 30:646.
4. Singer A, et al. 2008. Nat. Rev. Immunol. 8:788.
5. Zhu J and Paul WE. 2008. Blood 112:1557.
- Gene ID
- 920 View all products for this Gene ID
- UniProt
- View information about CD4 on UniProt.org
